Mary T. Szela

CIK: 0001410289

Transaction Breakdown

Open Market Buys (P)11 (39.3%)

High conviction signal

Open Market Sales (S)2 (7.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)14 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (3.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

TLSI

TriSalus Life Sciences, Inc.

DirectorOfficer

ABSI

Absci Corp

Director

KURA

Kura Oncology, Inc.

Director

ACAAU

Averin Capital Acquisition Corp.

Director

Discretionary Trading P&L

Holdings

Transaction History (28 total)

TLSI
TriSalus Life Sciences, Inc.
Oct 5, 2026
Tax Payment(F)
Direct
2.7K shares at avg. $4.38$12K
ABSI
Absci Corp
Jun 30, 2026
Purchase(P)
Direct
12.9K shares at avg. $11.54$149K
TLSI
TriSalus Life Sciences, Inc.
Jun 30, 2026
Award(A)
Direct
4K shares at avg. $3.87$15K
ABSI
Absci Corp
Jun 4, 2026
Award(A)
Direct
8.4K shares-
ABSI
Absci Corp
Jun 4, 2026
Award(A)
Direct
10.1K shares-
KURA
Kura Oncology, Inc.
Jun 4, 2026
Award(A)
Option to purchase common stock
Direct
35K shares-
TLSI
TriSalus Life Sciences, Inc.
May 15, 2026
Purchase(P)
Direct
39.7K shares at avg. $2.59$103K
TLSI
TriSalus Life Sciences, Inc.
Mar 17, 2026
Sale(S)
Direct
15.9K shares at avg. $3.85$61K
TLSI
TriSalus Life Sciences, Inc.
Mar 11, 2026
Sale(S)
Direct
4.4K shares at avg. $4.13$18K
TLSI
TriSalus Life Sciences, Inc.
Feb 23, 2026
Purchase(P)
Direct
30.5K shares at avg. $4.10$125K
TLSI
TriSalus Life Sciences, Inc.
Dec 31, 2025
Award(A)
Direct
2.1K shares at avg. $4.38$9K
TLSI
TriSalus Life Sciences, Inc.
Nov 24, 2025
Award(A)
Direct
300K shares-
TLSI
TriSalus Life Sciences, Inc.
Nov 24, 2025
Award(A)
Direct
125K shares-
ABSI
Absci Corp
Jul 7, 2025
Award(A)
Stock Option (right to buy)
Direct
178.4K shares-
TLSI
TriSalus Life Sciences, Inc.
Jun 30, 2025
Award(A)
Direct
2.8K shares at avg. $4.23$12K
KURA
Kura Oncology, Inc.
Jun 5, 2025
Award(A)
Option to purchase common stock
Direct
28.5K shares-
TLSI
TriSalus Life Sciences, Inc.
Feb 18, 2025
Award(A)
Direct
21.1K shares-
TLSI
TriSalus Life Sciences, Inc.
Jan 30, 2025
Purchase(P)
Direct
5K shares at avg. $5.28$26K
TLSI
TriSalus Life Sciences, Inc.
Jan 29, 2025
Purchase(P)
Direct
5K shares at avg. $5.03$25K
TLSI
TriSalus Life Sciences, Inc.
Jan 28, 2025
Purchase(P)
Direct
4.7K shares at avg. $5.12$24K
TLSI
TriSalus Life Sciences, Inc.
Jan 27, 2025
Award(A)
Direct
40K shares-
TLSI
TriSalus Life Sciences, Inc.
Jan 27, 2025
Purchase(P)
Direct
4.8K shares at avg. $5.42$26K
TLSI
TriSalus Life Sciences, Inc.
Dec 31, 2024
Award(A)
Direct
3.5K shares at avg. $4.26$15K
TLSI
TriSalus Life Sciences, Inc.
Sep 13, 2024
Purchase(P)
Direct
6K shares at avg. $5.00$30K
TLSI
TriSalus Life Sciences, Inc.
Sep 13, 2024
Purchase(P)
Direct
1.3K shares at avg. $4.83$6K

		Type	Shares	Price		Ownership
Oct 5, 2026	TLSI TriSalus Life Sciences, Inc.	Tax Payment(F)	2,693	$4.38	$11,795	Direct
Jun 30, 2026	ABSI Absci Corp	Purchase(P)	12,900	$11.54	$148,866	Direct
Jun 30, 2026	TLSI TriSalus Life Sciences, Inc.	Award(A)	3,990	$3.87	$15,441	Direct
Jun 4, 2026	ABSI Absci Corp	Award(A)	8,400	-	$0	Direct
Jun 4, 2026	ABSI Absci Corp	Award(A)	10,100	-	$0	Direct
Jun 4, 2026	KURA Kura Oncology, Inc.	Award(A) Option to purchase common stock	35,000	-	-	Direct
May 15, 2026	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	39,682	$2.59	$102,776	Direct
Mar 17, 2026	TLSI TriSalus Life Sciences, Inc.	Sale(S)	15,944	$3.85	$61,384	Direct
Mar 11, 2026	TLSI TriSalus Life Sciences, Inc.	Sale(S)	4,358	$4.13	$17,999	Direct
Feb 23, 2026	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	30,487	$4.10	$124,997	Direct
Dec 31, 2025	TLSI TriSalus Life Sciences, Inc.	Award(A)	2,100	$4.38	$9,198	Direct
Nov 24, 2025	TLSI TriSalus Life Sciences, Inc.	Award(A)	300,000	-	-	Direct
Nov 24, 2025	TLSI TriSalus Life Sciences, Inc.	Award(A)	125,000	-	-	Direct
Jul 7, 2025	ABSI Absci Corp	Award(A) Stock Option (right to buy)	178,400	-	-	Direct
Jun 30, 2025	TLSI TriSalus Life Sciences, Inc.	Award(A)	2,848	$4.23	$12,047	Direct
Jun 5, 2025	KURA Kura Oncology, Inc.	Award(A) Option to purchase common stock	28,500	-	-	Direct
Feb 18, 2025	TLSI TriSalus Life Sciences, Inc.	Award(A)	21,089	-	-	Direct
Jan 30, 2025	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	5,010	$5.28	$26,453	Direct
Jan 29, 2025	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	5,030	$5.03	$25,301	Direct
Jan 28, 2025	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	4,716	$5.12	$24,146	Direct
Jan 27, 2025	TLSI TriSalus Life Sciences, Inc.	Award(A)	40,000	-	$0	Direct
Jan 27, 2025	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	4,826	$5.42	$26,157	Direct
Dec 31, 2024	TLSI TriSalus Life Sciences, Inc.	Award(A)	3,530	$4.26	$15,038	Direct
Sep 13, 2024	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	6,000	$5.00	$30,000	Direct
Sep 13, 2024	TLSI TriSalus Life Sciences, Inc.	Purchase(P)	1,295	$4.83	$6,255	Direct

1-25 of 28 transactions

About Szela Mary T

Szela Mary T (SEC CIK 0001410289) files insider reports with the SEC as CEO and President of TriSalus Life Sciences, Inc. (TLSI), Director of Absci Corp (ABSI) and Director of Kura Oncology, Inc. (KURA). Signal8 also holds filings tied to 1 other company.

Signal8 holds 20 ownership filings by Szela Mary T (2 Form 3, 17 Form 4, 1 Form 5), filed between Sep 12, 2024 and Oct 7, 2026. Those filings report 28 transactions, from Feb 13, 2024 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Szela Mary T's filings is in WESTMINSTER, CO.

Recent filings by Szela Mary T

Oct 5, 2026: Tax withholding of TLSI shares (Form 4, code F).
Jun 30, 2026: Open-market purchase of ABSI shares (Form 4, code P).
Jun 30, 2026: Grant or award of TLSI shares (Form 4, code A).
Jun 4, 2026: Grants or awards of ABSI shares (2 lines, Form 4, code A).
Jun 4, 2026: Grant or award of KURA derivative securities (Form 4, code A).

Other insiders filing for TriSalus Life Sciences, Inc. (TLSI)

Cox Bryan F., Chief of Research
Marshak Richard, Chief Commercial Officer
Stevens Jennifer, Chief Regulatory Officer
Patience David, Chief Financial Officer
Marshall Richard Henry, Chief Medical Officer
Wahlstrom Mats, Director

How to read Form 4 transaction codes